Literature DB >> 22271402

Serum levels of daptomycin in pediatric patients.

C Antachopoulos1, E Iosifidis, K Sarafidis, F Bazoti, E Gikas, A Katragkou, V Drossou-Agakidou, E Roilides.   

Abstract

BACKGROUND: Limited data are available on the pharmacokinetics and optimal dosage of daptomycin, a lipopeptide compound possessing activity against Gram-positive bacteria, in the pediatric population, particularly in neonates and infants. We determined serum levels of daptomycin in hospitalized pediatric patients treated with various dosages of this agent.
METHODS: Blood samples were obtained from pediatric patients of all ages with normal renal function who had received daptomycin between May 2009 and December 2010. Serum levels prior ("trough") and 30 min after end of the infusion ("peak") were determined using an ultra-performance liquid chromatography-UV detection method.
RESULTS: A total of four daptomycin dosages and four patients were studied. Three patients were infants (gestational age: 29-38 weeks, age at sampling 26-65 days) and the fourth was a 7-year-old boy. A dosage of 6 mg/kg/12 h of daptomycin to the infants resulted in trough concentrations of <4-8.4 mg/l and peak concentrations of 10.9-17.7 mg/l. Comparable levels were observed after one of the infants received a dosage of 11 mg/kg/12 h, while a further dosage increase to 15 mg/kg/12 h yielded peak concentrations of 35.5 mg/l. The 7-year-old child received a daptomycin dosage of 12 mg/kg once daily; trough and peak levels were 4.2 and 103.4 mg/l, respectively.
CONCLUSIONS: A dosage of daptomycin 6 mg/kg/12 h in small infants results in lower peak and similar trough concentrations compared with a dosage of 4 mg/kg/day administered to adults. This results suggests that daptomycin dosages of more than 6 mg/kg/12 h may be needed for this pediatric age group to achieve a similar drug exposure as adults.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271402     DOI: 10.1007/s15010-011-0240-3

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

Review 1.  Tips and traps analyzing pediatric PK data.

Authors:  Brian J Anderson; Nick H G Holford
Journal:  Paediatr Anaesth       Date:  2011-03       Impact factor: 2.556

Review 2.  Physiological changes in the critically ill patient with sepsis.

Authors:  Shaun Hosein; Andrew A Udy; Jeffrey Lipman
Journal:  Curr Pharm Biotechnol       Date:  2011-12       Impact factor: 2.837

3.  Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.

Authors:  Mark Benvenuto; David P Benziger; Sara Yankelev; Gloria Vigliani
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

4.  Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.

Authors:  Susan M Abdel-Rahman; David P Benziger; Richard F Jacobs; Hasan S Jafri; Erica Fischer Hong; Gregory L Kearns
Journal:  Pediatr Infect Dis J       Date:  2008-04       Impact factor: 2.129

5.  Daptomycin use in infants: report of two cases with peak and trough drug concentrations.

Authors:  M Cohen-Wolkowiez; P B Smith; D K Benjamin; V G Fowler; K C Wade
Journal:  J Perinatol       Date:  2008-03       Impact factor: 2.521

6.  Daptomycin therapy for invasive Gram-positive bacterial infections in children.

Authors:  Monica I Ardura; Asunción Mejías; Kathy S Katz; Paula Revell; George H McCracken; Pablo J Sánchez
Journal:  Pediatr Infect Dis J       Date:  2007-12       Impact factor: 2.129

7.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

8.  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Authors:  Barry H Dvorchik; David Brazier; Michael F DeBruin; Robert D Arbeit
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

9.  Aminoglycoside volume of distribution and illness severity in critically ill septic patients.

Authors:  P E Marik
Journal:  Anaesth Intensive Care       Date:  1993-04       Impact factor: 1.669

10.  Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection.

Authors:  Abhijit Chakraborty; Sandip Roy; Juergen Loeffler; Ricardo L Chaves
Journal:  J Antimicrob Chemother       Date:  2009-04-22       Impact factor: 5.790

View more
  12 in total

1.  The Use of Daptomycin to Treat Methicillin-Resistant Staphylococcus Epidermidis Bacteremia in a Critically Ill Child with Renal Failure.

Authors:  Stephen Morris; Kate Gould; Lee P Ferguson
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

2.  Successful Use of Daptomycin in a Preterm Neonate With Persistent Methicillin-Resistant Staphylococcus epidermidis Bacteremia.

Authors:  Kristen M Gawronski
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jan-Feb

3.  Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy.

Authors:  B Preiswerk; A Rudiger; J Fehr; N Corti
Journal:  Infection       Date:  2012-07-21       Impact factor: 3.553

4.  Daptomycin Pharmacokinetics in Adolescents Undergoing Hemodialysis and Peritoneal Dialysis: A Case Series With Pharmacokinetic Modeling.

Authors:  Sin Yin Lim; Teresa Lewis; Sukyung Woo; Martin Turman; David W A Bourne; Michael E Burton; Pornpimol Rianthavorn
Journal:  J Pediatr Pharmacol Ther       Date:  2021-02-15

5.  Pharmacokinetics of Daptomycin in Critically Ill Pediatric Patients.

Authors:  Charalampos Antachopoulos; Stavroula Ilia; Paschalis Kadiltzoglou; Eirini Baira; Aristides Dokoumetzidis; Evangelos Gikas; Eleni Volakli; Maria Sdougka; George Briassoulis; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

6.  Methicillin-Resistant Staphylococcus aureus Endovascular Infection in a Neonate: Prolonged, Safe, and Effective Use of Daptomycin and Enoxaparin.

Authors:  Joshua I Chan; Asif Noor; Christie Clauss; Renu Aggarwal; Amrita Nayak
Journal:  J Pediatr Pharmacol Ther       Date:  2020 Jan-Feb

Review 7.  One Size Fits All? Application of Susceptible-Dose-Dependent Breakpoints to Pediatric Patients and Laboratory Reporting.

Authors:  Lindsey E Nielsen; Jeanne B Forrester; Jennifer Ellis Girotto; Aimee M Dassner; Romney Humphries
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

Review 8.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

Review 9.  Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.

Authors:  Martyn Gostelow; Daniel Gonzalez; P Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2014-04-09       Impact factor: 4.108

Review 10.  Advances in pediatric pharmacology, therapeutics, and toxicology.

Authors:  Daniel Gonzalez; Ian M Paul; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Adv Pediatr       Date:  2014-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.